Search

Your search keyword '"Dorsman JC"' showing total 69 results

Search Constraints

Start Over You searched for: Author "Dorsman JC" Remove constraint Author: "Dorsman JC"
69 results on '"Dorsman JC"'

Search Results

2. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes

4. DNA profiling of primary serous ovarian and Fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification

5. Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.

6. CRISPR screens in sister chromatid cohesion defective cells reveal PAXIP1-PAGR1 as regulator of chromatin association of cohesin.

7. Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma.

8. Retinoblastoma: From genes to patient care.

9. High-Level MYCN- Amplified RB1- Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures.

10. Detection of cytogenetic changes and chromosomal aneuploidy with fluorescent in situ hybridization in cytological specimens of oral cancers in Fanconi anemia-Proof of concept.

11. ELOF1 is a transcription-coupled DNA repair factor that directs RNA polymerase II ubiquitylation.

12. HSF2BP negatively regulates homologous recombination in DNA interstrand crosslink repair.

13. Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair.

14. Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells.

15. MR Imaging Features of Retinoblastoma: Association with Gene Expression Profiles.

16. Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

17. Genomic landscape of retinoblastoma in Rb -/- p130 -/- mice resembles human retinoblastoma.

18. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.

19. A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression.

20. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51.

21. The iron-sulfur cluster assembly network component NARFL is a key element in the cellular defense against oxidative stress.

22. FANCJ protein is important for the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation.

23. Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression.

24. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.

25. A reason for intermittent fasting to suppress the awakening of dormant breast tumors.

26. Coregulation of FANCA and BRCA1 in human cells.

27. RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients.

28. High resolution SNP array profiling identifies variability in retinoblastoma genome stability.

29. A protein prioritization approach tailored for the FA/BRCA pathway.

30. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

31. Huntingtin with an expanded polyglutamine repeat affects the Jab1-p27(Kip1) pathway.

32. Diagnosis of fanconi anemia: mutation analysis by next-generation sequencing.

33. Array comparative genomic hybridization analysis indicates that serous carcinomas of the ovary, fallopian tube and endometrium are distinct entities.

34. Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer.

35. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.

36. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.

37. HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study.

38. A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature.

39. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.

40. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

41. Identification of the Fanconi anemia complementation group I gene, FANCI.

42. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.

43. Small N-terminal mutant huntingtin fragments, but not wild type, are mainly present in monomeric form: Implications for pathogenesis.

44. Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases.

45. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.

46. Epitope mapping of monoclonal antibody 4C8 recognizing the protein huntingtin.

47. Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma.

48. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma.

50. Interruption of perfect CAG repeats by CAA triplets improves the stability of glutamine-encoding repeat sequences.

Catalog

Books, media, physical & digital resources